Newsroom

LOTTE BIOLOGICS (CEO Richard Lee) announced on the October 31 that it will attend the World ADC 2024 conference, taking place in San Diego, U.S., from November 4 to 7.

World ADC is a globally renowned event in the field of antibody-drug conjugates (ADC), now in its 15th year. The conference will feature over 140 ADC experts as speakers and bring together more than 1,200 industry professionals to share the latest research and technological trends, including keynote speeches, poster presentations, and discussion sessions. The event aims to facilitate active technology exchanges and business partnerships among pharmaceutical and biotech companies.

LOTTE BIOLOGICS will introduce the capabilities of its ADC production facility at the Syracuse Bio Campus and seek business partnership opportunities with new potential clients. The company also aims to keep pace with the latest trends in ADC technology to continually strengthen its competitive edge in providing one-stop ADC CDMO services.

LOTTE BIOLOGICS has a collaboration with several companies, including NJ BIO, a U.S.-based specialized Contract Research Organization (CRO), to provide this one-stop ADC CDMO service. LOTTE BIOLOGICS is pursuing open innovation through strategic partnerships and joint development of ADC technology platforms with ADC platform specialists Pinot Bio and Kanaph Therapeutics.

Moving forward, LOTTE BIOLOGICS plans to leverage the geographical advantages of its Syracuse Bio Campus for ADC manufacturing and distribution in the United States, enabling rapid and flexible responses to client needs. The ongoing ADC production facility expansion is aiming to receive Good Manufacturing Practice (GMP) certification by the first quarter of next year.

A LOTTE BIOLOGICS representative added, "Through this conference, we plan to further expand our global network and actively explore innovative collaboration opportunities based on ADC technology."